ICR | 'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines

'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines

The FDA is making some changes in the accelerated approval process. In this episode, we’ll discuss the recent changes with the FDA’s regulation of cancer drugs and how these shifts will impact the biopharma industry.

The oldest independent membership-led professional body for clinical researchers across the globe.